You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
人福醫藥(600079.SH):HZ-J001乳膏進入II期臨牀試驗研究

格隆匯5月8日丨人福醫藥(600079.SH)公佈,公司全資子公司武漢人福創新藥物研發中心有限公司(稱“創新藥研發中心”)的研發項目HZ-J001乳膏於近日在國家藥品監督管理局藥物臨牀試驗登記與信息公示平臺公示了II期臨牀試驗登記信息,其獲批的適應症爲:特應性皮炎、斑禿和白癜風。2025年4月,HZ-J001乳膏項目由成田藥業轉讓至創新藥研發中心。近日,HZ-J001乳膏治療非節段型白癜風的適應症進入II期臨牀試驗研究。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account